Results 81 to 90 of about 32,890 (266)

Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies [PDF]

, 2015
The idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of chronic disorders that include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM).
De Paepe, Boel, Zschüntzsch, Jana
core   +3 more sources

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisCapsule Summary

JAAD International
Background: DMB-3115 is a biosimilar to Stelara (hereinafter referred to as ustekinumab). Objectives: To evaluate the clinical similarity of DMB-3115 with ustekinumab in patients with moderate-to-severe plaque psoriasis.
Kamelia Vekovska, MD, Beata Imko-Walczuk, PhD, Martin Tichý, PhD, Zoe Diana Draelos, MD, Petra Cetkovska, PhD, Phoebe Rich, MD, Jolanta Weglowska, MD   +6 more
doaj   +1 more source

A case report of heart failure after therapy with ustekinumab

Journal of Dermatology and Dermatologic Surgery, 2015
Psoriasis is a chronic immune disorder that affects 2–3% of the US population. Ustekinumab, a monoclonal antibody against IL-23/12, has shown great efficacy in treating psoriasis. Here we present a rare finding of a patient with plaque-type psoriasis who
Kourosh Beroukhim, Melissa Danesh, Catherine Nguyen, John Koo, Argentina Leon   +4 more
doaj   +1 more source

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. [PDF]

, 2019
Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of
Lee, Erica B, Liao, Wilson, Pithadia, Deeti J, Reynolds, Kelly A, Wu, Jashin J   +4 more
core  

Secukinumab: a new treatment option for psoriatic arthritis [PDF]

, 2016
Introduction: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life.
McInnes, Iain B., Mease, Philip
core   +1 more source

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease

Journal of Clinical Medicine, 2023
Monitoring of anti-drug antibodies in patients on ustekinumab is not routinely recommended in patients with inflammatory bowel disease (IBD) due to low rates of immunogenicity.
X. Roblin, G. Duru, K. Papamichael, A. Cheifetz, S. Kwiatek, A. Berger, M. Barrau, L. Waeckel, S. Nancey, S. Paul   +9 more
semanticscholar   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

Pediatric Drugs
Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety of ustekinumab in pediatric UC and IBDU.
S. Cohen, H. Rolandsdotter, K. Kolho, Dan Turner, C. Tzivinikos, M. Bramuzzo, G. Pujol-Muncunill, L. Scarallo, D. Urlep, F. Rinawi, M. Granot, Ben Kang, Ylva Longueville, M. V. Rodríguez-Belvís, Y. Weintraub, V. Navas‐López, A. Yerushalmy-Feler   +16 more
semanticscholar   +1 more source

Precision Imaging for Optimized Crohn's Disease Management: Navigating the Evolution of Objective Healing Goals

iRADIOLOGY, EarlyView.
Multimodal imaging enables the transition to transmural healing as a superior therapeutic target in Crohn's disease, facilitating precise stricture characterization and the prediction of long‐term clinical outcomes. Some icons are sourced from Figdraw and have been authorized (ID: ROSUUdd4c2).
Ziman Xiong, Yufan Wang, Shuxin Luo, Zhen Li, Yaqi Shen   +4 more
wiley   +1 more source